The epidermal growth factor receptor (EGFR) is a multi-sited and multifunctional transmembrane glycoprotein with intrinsic tyrosine kinase activity. Upon ligand binding, the monomeric receptor undergoes dimerization resulting in kinase activation. The consequences of kinase stimulation are the phosphorylation of its own tyrosine residues (autophosphorylation) followed by association with and activation of signal transducers. Deregulation of signaling resulting from aberrant expression of the EGFR has been implicated in a number of neoplasms including breast, brain, and skin tumors. A mutant epidermal growth factor (EGF) receptor missing 267 amino acids from the exoplasmic domain is common in human glioblastomas. The truncated receptor (EGFRvIII/∆EGFR) lacks EGF binding activity; however, the kinase is constitutively active and cells expressing the receptor are tumorigenic. Our studies revealed that the high kinase activity of the ∆EGFR is due to self-dimerization and contrary to earlier reports, the kinase activity per molecule of the dimeric ∆EGFR is comparable to that of the EGFstimulated wild-type receptor. Further, the phosphorylation patterns of both receptors are similar as determined by interaction with a conformation-specific antibody, and by phosphopeptide analysis. This eliminates the possibility that the defective down-regulation of the ∆EGFR is due to its altered phosphorylation pattern as has been suggested previously. Interestingly, the receptor-receptor self-association is highly dependent on a conformation induced by N-linked glycosylation. We have identified four potential sites that might participate in self-dimerization; these sites are located in a domain which plays an important role in EGFR functioning.
INTRODUCTION
The human epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein with a cysteine-rich extracellular region, and an intracellular domain containing uninterrupted kinase site, and multiple autophosphorylation sites clustered at the C-terminal tail (1,reviewed in 2; see Fig. 1 ). On the basis of internal sequence identity, the extracellular portion of the EGFR has been subdivided into four domains: domains I (amino acids 1-165) and III (310-481) have 37% sequence identity whereas domains II (166-309) and IV (482-621) are rich in cysteines (3; see Fig. 1 ); these cysteines are linked by intra-chain disulfide bonding (4) . Domain III has been shown to bind directly with EGF and then two molecules of the monomeric receptor-ligand complex interact to form a dimeric complex. Domain I is believed to be involved in the second interaction (3, 4) . The receptor dimerization results in kinase activation. The earliest consequence of kinase activation is the phosphorylation of its own tyrosine residues (autophosphorylation) and this is followed by its association with and activation/phosphorylation of signal transducers leading to mitogenesis. In addition, we have demonstrated a phosphorylation-induced conformational alteration of the EGFR (5) . Such conformational change agrees well with the finding that autophosphorylation also results in unmasking of cryptic cytoplasic domain(s) needed for receptor internalization (6) .
Deregulation of signaling due to the aberrant expression of the EGFR has been implicated in oncogenesis. Nearly 50% of grade IV gliomas (glioblastoma multiforme) have amplified EGFR genes. In the majority of such cases, the EGFR gene amplification is correlated with structural rearrangement of the gene, resulting in in-frame deletions that preserve the reading frame of the receptor message. To date, three truncated forms of EGFR have been identified (7) (8) (9) . The type Core glycosylation in self-dimerization of EGFRvIII III deletion mutant occurs in 17% of the glioblastomas and is characterized by an 801-bp inframe deletion resulting in the removal of NH 2 -terminal amino acid residues 6 through 273 from the extracellular domain of the intact 170-kDa EGFR (9; see Fig. 1 ). Although there is a consensus that this truncated receptor (EGFRvIII/∆EGFR) lacks ligand binding activity and the kinase is constitutively active (10) (11) (12) , the subcellular localization of the receptor has not yet been conslusively established. In some transfectants, a significant fraction of the receptor population was reported to be intracellular (10, 11) whereas studies from another laboratory appear to suggest that the receptors are predominantly on the cell surface (12) . In addition, the molecular mechanism by which the transfectants acquire transforming activity is not clear.
Studies from Cavenee's group suggest that constitutive activation of Ras-MAP kinase pathway contributes to the transforming activity of the ∆EGFR (13) whereas Wongs group has demonstrated that the transformation is mediated through constitutive activation of phosphatidylinositol 3-kinase and c-Jun N-terminal kinase and not through Ras-MAP kinase pathway (14, 15) .
Although the ∆EGFR undergoes ligand-independent kinase activation, the extent of autophosphorylation of the ∆EGFR is significantly less compared to that of the ligandstimulated WtEGFR (11, 16) . Since phosphorylation-induced conformational change results in exposure of sequence motifs involved in endocytic and lysosomal sorting and such unmasking is thought to be obligatory for receptor down-regulation (6) , this may explain the persistent presence of the ∆EGFR on the cell surface. It is possible that the endocytic codes are cryptic in Biotech Research and Resourse (Upland, PA). EGF was purified from mouse submaxillary glands and radiolabeled with 125 I by the chloramine-T procedure (17) . Solid-phase EGF was prepared by coupling EGF to Affi-Gel 15 (Bio-Rad, Hercules, CA) as described (17) . Labeled ATP was prepared with 32 P i and γ-Prep A kit (Promega, Madison, WI) according to the manufacturers directions. Specific radioactivity of [γ-32 P]ATP was adjusted by adding unlabeled ATP (17) . All radioisotopes were purchased from ICN Biomedicals (Costa Mesa, CA).
Iodination of mAb 425---
The monoclonal antibody directed to an extracellular peptide epitope of the human EGFR (19) was iodinated by the chloramine T method. 5 µg of protein A-purified mAb 425 in a total volume of 20 µl containing 0.15 M sodium phosphate, pH 7.5 and 0.25 mCi of Na 125 I was incubated at 20 0 C with 30 µg of chloramine T. After 1 min, the iodination reaction was terminated by the addition of sodium metabisulfite followed by NaI and BSA.
Under these conditions nearly 50% of 125 I was incorporated into the protein as determined by TCA precipitation. The labeled antibody was separated from the free radioactivity by Sephadex G-10 chromatography.
EGFR mutants and cell culture---Human glioblastoma cell line, U87MG, as well as cells expressing the truncated receptor lacking the EGF binding activity and the wild-type receptor were obtained from Drs. W. K. Cavenee and H.-J. Su Huang. The generation and characterization of the mutant have previously been described (16) . The transfected cells were grown in DMEM containing 10% heat inactivated cosmic bovine serum (Hyclone, Logan, UT) and 0.4 mg/ml G418; parental U87MG cells were grown in the absence of G418. Plasma membranes from these cells were prepared as described (17) .
Core glycosylation in self-dimerization of EGFRvIII
Receptor sites/cell were determined by 125 I-EGF binding assay as described previously (17) . Briefly, 2.25 ng of 125 I-EGF (5.6x10 5 cpm) in a total volume of 200 µl of Earles balanced salt solution containing 20 mM HEPES, pH 7.5, 2.5 mg/ml BSA and unlabeled EGF (25 ng/ml for cells expressing less than 1x10 5 receptor sites/cell and 100 ng/ml for cells expressing more than 1x10 5 receptor sites/cell) were incubated at 20 0 C for 2 h with cells grown in 2 cm 2 24-well plates. Non-specific binding, which was 5-10% of the total binding, was measured by incubating the cells with labeled EGF in the presence of 200 nM unlabeled EGF. The EGF binding sites/cell in different mutants are shown in Table 1 .
For antibody binding, 13 ng of 125 I-labeled mAb 425 (2x10 6 cpm) mixed with 30 ng of unlabeled antibody was incubated with cells under conditions described above. This represents the saturating concentration of the antibody for the receptor binding. Non-specific binding which was 2-3% of the total binding was determined by incubating cells with labeled antibody in the presence of 50-fold excess of unlabeled antibody.
Biosynthetic labeling of the EGFR---This was done as described (17) except that incubation with Tran-35 S-label (100 µCi/ml; 1190 Ci/mmole) was carried out in methionine-and cysteine-free DMEM containing 2% cosmic bovine serum.
Antibodies---Anti-peptide antibody Ab P2 is directed to amino acid residues 964-979 (GluGly-Tyr-Lys-Lys-Lys-Tyr-Gln-Gln-Val-Asp-Glu-Glu-Phe-Leu-Arg) of the cytoplasmic domain of the human β-type PDGFR. It was generated in rabbits using HPLC-purified peptide according to method described previously (20) . Monoclonal antibody, mAb 425, raised against human A431 carcinoma cells and polyclonal 170-kDa antibody to denatured EGFR were gifts from Dr. M. Das and were developed as described (19, 21 antibody which is suitable for kinase assay is directed to the C-terminus of the receptor. The mouse monoclonal anti-phosphotyrosine antibody, 1G2, used for purification of the tyrosine phosphorylared proteins, was generated as described and coupled to activated sepharose (22) . (17) (5) . An aliquot of the labeled proteins purified by anti-phosphotyrosine monoclonal antibody (1G2) was subjected to immunoprecipitation with an antibody directed to a cytoplasmic domain of the EGFR, analyzed by SDS-PAGE, and quantified as described (17) . The quantification of the receptor protein is based on the assumption that there is no incorporation of 32 P into Ser/Thr residues of the EGFR.
Quantification of the 32 P-labeled EGFR---This was carried out as described
This assumption was validated in an earlier report that no 32 P-labeled human EGFR could be detected in MI41, a murine NIH 3T3 cell line expressing a human EGFR mutant in which all five acceptor tyrosine residues have been substituted with phenylalanine (17) .
Chemical cross-linking of the EGFR---
The detergent-solubilized plasma membranes or 32 Plabeled receptor preparation was incubated with BS 3 at 4 0 C for 10 min (23, 24) . Excess crossCore glycosylation in self-dimerization of EGFRvIII linker was inactivated by the addition of Tris, pH 7.5, and the samples were processed as described in the figure legends.
Immunoprecipitation technique and electrophoresis---These were carried out as described (17) .
Briefly, the labeled receptor preparation was incubated with the indicated antibody at 4 0 C overnight in 15 µl (unless otherwise indicated) of 20 mM HEPES, pH 7.4, 0.15 M NaCl, 0.2% NP-40, 2.5 mg/ml BSA, 1 mM vanadate, and protease inhibitors. After isolation of the immune complexes by protein A-sepharose, the receptors were analyzed by SDS-PAGE (7% gel unless otherwise indicated) and the labeled bands were visualized either by autoradiography (for 32 P- Western-blot analysis---This was carried out as described (25) . Briefly, the electrophoretically separated proteins were transferred to poly(vinylidene difluoride) membranes (Millipore Corp., Bedford, MA) by electrophoresis at 4 0 C overnight at 0.1 mA followed by 1.5 h at 0.2 mA. After incubation with an antibody as specified in figure legends, the antigen-antibody complex was visualized either by ECL Plus reagents from Amersham (Piscataway, NJ) or by 125 I-protein A.
The intensity of the band was quantified using Image Quant program. The pre-stained molecular weight markers used (with apparent molecular weight) were α 2 -macroglobulin (200-k), β-galactosidase (123-k), fructose-6-phosphate kinase (84-k), and pyruvate kinase (63-k).
Phosphopeptide analysis---For phosphopeptide mapping, 32 P-labeled wild-type EGFR was purified by EGF-Affi-Gel chromatography as described (17) were then subjected to reverse-phase HPLC analysis using a DeltaPak 6µ C 18 column (Waters;
Column size : 3.9x150 mm) as described (17) . Briefly, following injection, the column was washed with 10 ml of 0.1% trifluoroacetic acid in water and then the phosphopeptides were eluted with a 0-60% acetonitrile gradient containing 0.1% trifluroacetic acid with a flow rate of 1 ml/min. 0.5 ml fractions were collected and the Cerenkov counts were determined. Kinase assay---This was performed as described (18) with some modifications. Briefly, the EGFR was immunoisolated using a polyclonal antibody coupled to agarose; this antibody is directed to a cytoplasmic domain of the receptor. After washing three times, the gel beads were incubated in a total volume of 50 µl containing 20 mM Hepes, pH 7.5, 5% glycerol, 0.1% NP- TCA was added to the supernatant to a final concentration of 5%. BSA was added as carrier protein to facilitate the precipitation of the EGFR that might have dissociated from the antibody during the incubation. After 10 min at 4 0 C, the reaction mixture was centrifuged in cold and the supernatant was processed as described to determine the substrate phosphorylation (18) .
Sucrose density gradient ultracentrifugation---This was carried out as described (23) 
Isolation of endoplasmic reticulum from tunicamycin-treated cells---This was carried out as
described (26) . Briefly, confluent cultures of cells grown in p150 plates were incubated at 37 0 C for 20 h in growth medium containing 1µg/ml tunicamycin. Under these conditions, the newly http://www.jbc.org/ Downloaded from from these cells as described (26) .
RESULTS
Mutation of the EGFR resulting in type III truncation occurs spontaneously in in vivo in glioma cells. This led us to use a human glioma cell line, U87MG, as the host for the expression of the ∆EGFR/EGFRvIII and, as a control, the wild-type receptor. The ∆EGFR maintains its transforming activity in this host cell. Another advantage in selecting this cell line is that it is deficient in endogenous EGFR (see below). Table 1 ).
Receptor numbers per cell in U87MG.∆EGFR---Earlier
To investigate whether the estimated numbers of antibody binding sites reflect the actual receptor sites, we also determined the receptor numbers in U87MG.WtEGFR using 125 I-EGF binding and compared it with the antibody binding sites. As shown in Table 1 sites/cell) and it represents less than 5% of the truncated receptor population. This is further confirmed by Western blot analysis followed by densitometric scanning of the 170-kDa wildtype receptor band and the 145-150-kDa truncated receptor band (Fig. 2) .
Isolation of the dimeric ∆EGFR in biologacally active state and its kinase activity ---Based on
chemical cross-linking studies in which intact cells were reacted with a cross-linker, it was concluded that the autokinase activity of the ∆EGFR is 20% of that of the EGF-stimulated wildtype receptor (11, 16) . Since the ∆EGFR is capable of self-dimerization, it implies that receptor dimerization is obligatory but not sufficient for full kinase activation. Hence to examine the extent of dimerazation and more importantly to investigate the kinase activity of the dimeric receptor, sedimentation studies were performed to isolate the monomeric and dimeric forms of the ∆EGFR in biologically active state. For this purpose the WGA-agarose-purified receptors from U87MG.∆EGFR cell membranes were subjected to sucrose sedimentation analysis and the kinase activity of the gradient fractions was assayed by autophosphorylation. As control, the WtEGFR was also subjected to sedimentation analysis under similar conditions; however, the gradient fractions were assayed by autophosphorylation in the presence of EGF. The identity of the EGFR in the gradient fractions was confirmed by immunoprecipitation with mAb 425
antibody. As shown in Fig. 3 , the ∆EGFR exists in two forms a slow moving form and a fast moving form; however, under similar conditions the WtEGFR moves as a single entity with a mobility similar to that of the slow moving component of the ∆EGFR. To determine the molecular weights of the different components, we analyzed the peak fractions by chemical cross-linking. For this purpose, the 32 P-labeled receptor preparations were subjected to chemical cross-linking with 50 µM BS 3 , immunoprecipitated with mAb 425 and then analyzed by SDS-PAGE. As shown in Fig. 3 (inserts), following BS 3 treatment of the faster moving peak from the ∆EGFR, a cross-linked complex corresponding to a molecular weight of ~300-k could be detected; the receptor population that escaped cross-linking is present as an 145-150-kDa band. The 145-150-kDa band and not the 300-kDa band was seen when cross-linking was carried out with the slower moving peak. These suggest that the fast and the slow moving components of the ∆EGFR represent the dimeric and the monomeric forms of the receptor, respectively. No cross-linked complex could be seen when the peak fraction from the WtEGFR was subjected to BS 3 treatment and the 32 P-labeled receptor moved as an 170-kDa protein, a molecular weight consistent with the monomeric form of the receptor. For the experiment described in Fig. 3 , the truncated receptor has undergone a series of treatments that not only took more than 10 h to complete but also resulted in significant receptor dilution. In spite of these treatments, a significant portion of the ∆EGFR exists in the dimeric state.
We also determined the specific activity of monomeric ∆EGFR kinase. For this purpose we quantified both the wild-type and the truncated receptors in the gradient fractions by Western blot analysis using a polyclonal antibody directed to the denatured 170-kDa EGFR (see Fig. 4 ).
Both the receptors were also quantified by probing the blot with a monoclonal antibody directed 4 ). This suggests that receptor dimerization, at least with respect to the ∆EGFR, is sufficient for full kinase activation.
Interaction of the ∆EGFR with an antibody that recognizes only the activated receptor---The
studies described above revealed that there is no difference with respect to kinase activity between the ∆EGFR which undergoes dimerization in the absence of the ligand and the EGFstimulated wild-type receptor. This led us to investigate whether the phosphorylation pattern and phosphorylation-mediated conformational change of the receptors are also similar. Such information is important since it has been proposed that the slow endocytic rate of the ∆EGFR is due to its altered phosphorylation (16) . For this purpose we studied the interaction of a (Fig. 5 ). This indicates that the affinity of the antibody for both receptor types is similar and the phosphorylation pattern, at least with respect to Tyr 992, 1068, and 1086, of the ∆EGFR is comparable to that of the WtEGFR. This is further confirmed by phosphopeptide analysis of the receptors. The HPLC elution profiles of the phosphopeptides from the ∆EGFR were similar to that of the WtEGFR (Fig. 6 ). This suggests that the inefficient internalization of the ∆EGFR is not due to its altered phosphorylation.
Glycosylation-induced conformational modification and kinase activation of the ∆EGFR---
The EGFR is a glycoprotein and it has 12 potential N-linked glycosylation sites (1; see Fig. 1 ).
Earlier studies have demonstrated the importance of core glycosylation in EGF binding and aglyco-∆EGFR synthesized in the presence of tunicamycin is also not capable of binding with the antibody (data not shown). As discussed above (see Table 1 ), this monoclonal antibody is directed to an extracellular peptide epitope of the EGFR (19) and it also recognizes the ∆EGFR. (Table 2) . In this assay, equal amounts of the glycosylated-and aglyco-receptors (quantified by Western blot using an C-terminal anti-EGFR antibody) were immunoisolated by a polyclonal anti-EGFR antibody coupled to agarose and then the kinase activity in the gel beads was assayed by phosphorylation of an EGFR substrate (18) . As with the autokinase assay, the extent of phosphorylation of the substrate by the aglyco-receptor was much less compared to that of the control receptor (Table 2) . Thus, as with the EGFR, core glycosylation of the ∆EGFR is needed to generate a conformation which eventually leads to its kinase activation.
We also investigated the mechanism by which the carbohydrate chains are involved in kinase activation. One possibility is that the oligosaccharide chains participate directly in kinase stimulation and removal of the carbohydrate chains reverts the receptor back to its kinaseinactive state. Alternatively, the function of the N-linked glycosylation is to impart a stable kinase-active conformation to the receptor and once the receptor attains such a conformation, the carbohydrate chains are dispensible. To distinguish between these two possibilities, we studied the effect of enzymatic removal of the carbohydrate chains from the mature ∆EGFR on its kinase activity. One such enzyme is endoglycosidase H which cleaves between the Nacetylglucosamine residues of the chitobiose unit of N-glycans that are linked to asparagine. The high-mannose form of the truncated receptor which is a substrate for the enzyme was antibody, the intensity of the treated band was similar to that of the control band. Thus, the modified receptor of M r ~140k is as active as the control receptor (Fig. 8A) . Similar results were also seen by exogenous substrate assay (data not shown). These suggest that terminal processing blocked by swainsonine is not required for kinase activation. Deglycosylation of the highmannose receptor by treatment with endoglycosidase H results in a protein of M r ~115k (see but not its terminal processing is sufficient for kinase activation and (ii) the function of the glycosylation is to impart a kinase-active conformation to the ∆EGFR and it does not revert back to its kinase-inactive conformation upon deglycosylation.
Aglyco-∆EGFR synthesized in the presence of tunicamycin lacks dimer forming ability ---
Since self-dimerization/oligomerization is obligatory for ∆EGFR kinase stimulation, we investigated whether the reduced kinase activity of the aglyco-receptor is due to its loss of dimer forming ability. It should be mentioned in this connection that based on quantifying receptor protein by Western blot, the autokinase activity of the aglyco-∆EGFR is 10-20% of the glycosylated receptor (data not shown). This agrees well with our finding that the kinase activity of the dimeric ∆EGFR is 5-7-fold higher relative to the monomeric receptor (see Fig. 4 ). To test were subjected to cross-linking with 150 µM BS 3 and following immunoprecipitation by a receptor-specific antibody, the cross-linked receptors were subjected to Western blot analysis.
In glycosylated receptor, a 300-kDa band as well as a band at ~145-150-kDa could be seen following cross-linking (Fig. 9B, lane 2) . The 300-kDa band could not be seen when no crosslinker was used (Fig. 9B, lane 1) . However, under similar conditions, no cross-linked complex could be seen when the aglyco-receptor was treated with BS 3 (see Fig. 9B , lane 4) although the 115-kDa band corresponding to the monomeric form of the receptor was present. No crosslinked complex could be seen when BS 3 concentration was increased to 300 mM (data not shown).
DISCUSSION
The major findings of our studies are as follows : (i) The hyperactivation of the ∆EGFR is due to its stable receptor-receptor self-association; (ii) The extent of kinase activation and the phosphorylation pattern of the ∆EGFR resulting from its self-dimerization are the same as that of the ligand-induced dimerization of the WtEGFR , and interestingly (iii) The self-dimerization of the ∆EGFR leading to kinase activation is highly dependent on a conformation induced by core glycosylation. These studies were conducted by expressing both receptor types in U87MG, a glioblastoma cell line. Our binding studies with 125 I-labeled mAb 425 revealed that the expression levels of both receptor types are comparable. In addition, the endogenous receptor level in host cell is also low (~5% of the truncated receptor) (see Table 1 ). It should be mentioned in this connection that the ∆EGFR binding sites/cell determined in the present study differ significantly from the one reported by Huang et al (16) During the isolation of the dimeric form of the ∆EGFR by sucrose gradient centrifugation, the receptor preparation has undergone series of experimental manipulations that not only took considerable time to complete but also resulted in significant dilution of the receptor. In spite of these, nearly 40% of kinase activity could be recovered in a dimeric state suggesting that the receptor-receptor interaction is highly stable. Thus, it is likely that under in vivo conditions in which the receptor concentration is very high (due to amplification), the ∆EGFR will be predominantly in dimeric form. Our studies also revealed that on a molar basis, the kinase activity of the dimeric receptor is 5-7-fold higher compared to that of the monomeric receptor. We also showed that the kinase activity per molecule of the dimeric ∆EGFR is similar to that of the EGF-stimulated WtEGFR as determined by autophosphorylation assay. This is in contrast to the earlier studies which reported that the kinase activity as determined by phosphotyrosine content per molecule of the ∆EGFR is only 13-20% of the WtEGFR stimulated by EGF (13, 16) . Those studies were further supported by the finding that only 20% of the receptor population could be chemically cross-linked. However, it should be noted that chemical The facts that the affinity and the extent of binding of the conformation-specific antibody, Ab P2, with the ∆EGFR are similar to that of the EGF-activated wild-type receptor (Fig. 5) suggest a similar phosphorylation-induced conformational change of both the receptors.
It should be mentioned in this context that Ab P2 recognizes an epitope in the intracellular domain of the EGFR which is unmasked only upon phosphorylation of tyrosines 992, 1068, and 1086, located in the C-terminal tail of the receptor, as a unit. This suggests that the ∆EGFR is recognized by the antibody as an active molecule. This is further supported by the phosphopeptide analysis which revealed that there is no difference in the phosphorylation pattern of the ∆EGFR with that of the wild-type receptor stimulated by EGF (Fig. 6) . Thus whether the receptor undergoes self-dimerization (as is the case with the ∆EGFR) or ligand-induced dimerization, the outcome is the same. Our results and hence the conclusion are in contrast to earlier report which correlated the inefficient down-regulation of the ∆EGFR with its low autokinase activity and hence altered phosphorylation pattern. Since phosphorylation-induced exposure of the otherwise cryptic endocytic sequence motifs is needed for receptor internalization and down-regulation (6), Huang et al (16) suggested that the cryptic internalization codes are not exposed in the ∆EGFR. Since we could not detect any altered phosphorylation pattern of the ∆EGFR in relation to the wild-type receptor, it suggests that the defective endocytosis is not due to low or altered phosphorylation but due to a mechanism which
is not yet clear. Thus the high tumorigenic activity of the ∆EGFR is probably not only due to the persistent presence of the receptor on the cell surface as has been suggested (16) but is also possibly due to the higher kinase activity of the dimeric receptor generated by self-association. It should be mentioned that due to high stability of the dimeric receptor, most of the receptor population under in vivo situation will be present in dimeric state.
The importance of the carbohydrate chains on the conformation of the ∆EGFR is underscored by our finding that like the aglyco-WtEGFR, ∆EGFR synthesized in the presence of tunicamycin fails to bind a monoclonal antibody, mAb 425, directed to a peptide epitope in the extracellular domain of the EGFR (data not shown). This antibody, however, binds to the wildtype as well as truncated EGFR (see Table 1 with WGA-agarose and the flow-through was used as the source for the Tu-treated receptor.
Isolated plasma membranes fron untreated cells were used as the source for control receptor.
Equal amounts of the Tu-treated receptor and the control receptor (quantified by Western blot analysis using a monoclonal antibody, Ab-15, directed to a cytoplasmic epitope) were immunoisolated using a polyclonal antibody coupled to agarose. This antibody is directed to an intracellular domain of the receptor. The kinase activity of the washed gel beads was measured by determining the incorporation of 32 P into the peptide substrate under conditions described in "Experimental Procedures". ATP under autophosphorylation conditions. After dissociation from gel beads by heating with SDS-sample buffer, the 32 P-labeled receptors were subjected to SDS-PAGE, digested with trypsin and then 100000 cpm were analyzed by reverse phase HPLC as described under "Experimental Procedures". ¢, WtEGFR; p, ∆EGFR. 
